Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
DS-234 in Eczema: NCT07453602 Clinical Landscape Report 2026
28 September 2026
NCT07453602 clinical landscape for Eczema: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
S-4321 in Lupus Erythematosus, Cutaneous: NCT07455578 Clinical Landscape Report 2026
28 September 2026
NCT07455578 clinical landscape for Lupus Erythematosus, Cutaneous: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ivosidenib in Acute Myeloid Leukemia: NCT07463768 Clinical Landscape Report 2026
28 September 2026
NCT07463768 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ruxolitinib Phosphate in Relapsing acute myeloid leukemia: NCT07464951 Clinical Landscape Report 2026
28 September 2026
NCT07464951 clinical landscape for Relapsing acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
Bevacizumab in Ovarian Cancer: NCT07472140 Clinical Landscape Report 2026
28 September 2026
NCT07472140 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Famitinib Malate in Uterine Cervical Cancer: NCT07466901 Clinical Landscape Report 2026
28 September 2026
NCT07466901 clinical landscape for Uterine Cervical Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CD84 Targeted CART(Gyala Therapeutics) in Acute Myeloid Leukemia: NCT07471789 Clinical Landscape Report 2026
28 September 2026
NCT07471789 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Benmelstobart in Recurrent Cervical Cancer: NCT07472153 Clinical Landscape Report 2026
28 September 2026
NCT07472153 clinical landscape for Recurrent Cervical Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Daphnetin in Ovarian Epithelial Carcinoma: NCT07495397 Clinical Landscape Report 2026
28 September 2026
NCT07495397 clinical landscape for Ovarian Epithelial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Roflumilast in Psoriasis vulgaris: CTRI/2026/03/0106289 Clinical Landscape Report 2026
28 September 2026
CTRI/2026/03/0106289 clinical landscape for Psoriasis vulgaris: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
D-215 in BRCA-mutated Fallopian Tube Carcinoma: NCT07532148 Clinical Landscape Report 2026
28 September 2026
NCT07532148 clinical landscape for BRCA-mutated Fallopian Tube Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
EB-NK-MF in Primary peritoneal carcinoma: NCT07480954 Clinical Landscape Report 2026
28 September 2026
NCT07480954 clinical landscape for Primary peritoneal carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.